molinskym; You seem to have a real interest in this company - care to share your reasons why? Unfortunately this is a very nasty time for biotechs as the sector move is into commodities. Our idiot leaders have created a situation whereby money is not focused towards R&D.
There was a mention of Alnylam in Scientific American Oct. issue. Alnylam is an Arabic name meaning "string of pearls".
My question to you; under what business model do you see Alnylam getting to a point of making money with the very little cash they have?
Hmmmm....well if I had to pick the one main reason why I'm interested in this company, it's because there seems to be widespread expectation that RNAi has significant potential and secondarily that AMD seems to be a good place to start exploring the feasibility of this approach. Beyond that, the people doing the research at this company appear competent.
As to when the company might start making money, i.e., a balance sheet that's not in the red, I'd hazard a guess at about five years from now, which is why my investment in this company is a long term position and I'm looking to buy on the dips.
Frankly, barring some astonishing breakthroughs, I don't see how there's any quick turnaround on investment here, but you never know. Good luck to you.